John Leonard, President and Chief Executive Officer, Intellia Therapeutics: It is. I would say that the patient population that you’ve seen in the Acaramidis study as well as Helios B is pretty ...

Intellia continues to maintain a solid balance ... There is a low event rate in this population suggesting that the patients are benefiting from therapy both in terms of stabilization and even ...

Intellia's projections represent the worldwide markets for ATTR amyloidosis and hereditary angioedema, but the target patient population will be smaller. For instance, Intellia's ongoing phase 3 ...

Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics ... progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure ...

Novel approaches: Gene editing therapies like NTLA-2001 from Intellia Therapeutics offer ... may lead to wider adoption across the ATTR-CM patient population. 3. Combination therapy potential ...

At least a half-dozen drug companies have been racing to develop treatments for AATD, lured by what seemed like tractable genetics and a sizable patient population. In addition to the few thousand ...

Furthermore, emerging gene editing approaches, such as Intellia Therapeutics (NASDAQ ... The current estimates of the ATTR-CM patient population may be conservative. Some analysts believe the ...

Novel approaches: Gene editing therapies like NTLA-2001 from Intellia Therapeutics offer the promise of ... may lead to wider adoption across the ATTR-CM patient population. 3. Combination therapy ...

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for ...